Company news
Sol-gel Technologies Ltd. (NASDAQ:SLGL) news
Sol-gel Technologies Ltd. news releases on 6ix. Latest, Nov 9, 2021: Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
Press releases — page 2
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
November 8, 2021
Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
November 3, 2021
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
September 21, 2021
Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
September 8, 2021
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
August 3, 2021
Sol-Gel Technologies Announces FDA Approval of TWYNEO®
July 26, 2021
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
July 19, 2021
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
June 27, 2021
Sol-Gel Announces Pipeline Update and Future Development Plans
June 27, 2021
Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
May 26, 2021
Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
May 12, 2021
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
April 26, 2021
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
February 23, 2021
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
January 10, 2021
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
December 6, 2020
Successful Completion of the COVID-19 Sol-Gel Formulation Development
November 24, 2020
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
November 11, 2020
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
November 8, 2020
Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
November 3, 2020
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea
September 9, 2020
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September
September 7, 2020
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®
September 2, 2020
Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update
August 5, 2020
Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
July 28, 2020
Sol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021
July 27, 2020
Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates
June 28, 2020
Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
June 15, 2020
Sol-Gel to Present at Upcoming Healthcare Investor Conferences
May 26, 2020
Sol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update
May 13, 2020
Sol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020
May 6, 2020
Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment
April 12, 2020
Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference
March 24, 2020
Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update
March 23, 2020
Sol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate Update
March 18, 2020
Sol-Gel to Present at the Cowen 40th Annual Health Care Conference
February 18, 2020
Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares
February 13, 2020
Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks
February 12, 2020
Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020
February 4, 2020
Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
January 20, 2020
Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris
January 7, 2020
Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)
January 1, 2020
Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris
December 29, 2019
Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update
November 12, 2019
Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
October 15, 2019
Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
April 17, 2019
Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris
April 14, 2019